Phacilitate Leaders World

Sponsors & Exhibitors

Sponsors & Exhibitors

  • Letter
    • O
  • Optel Group

    Stand: 2
    A Secure and Intelligent Supply Chain for Cell and Gene/CAR-T Therapies These revolutionary therapies have created a brand-new supply chain with unique needs. End-to-end visibility, uniquely identifie ...
  • Organicell

    Stand: WSC7 and WSC8
    Organicell is the leading, fully integrated Exosome Therapeutics Company. Our world class research, technology, manufacturing and clinical development team is focused on creating new biologic medicine ...
  • OriGen Biomedical

    Stand: 802
    OriGen Biomedical designs, manufactures and distributes a complete line of products for use in CAR T-Cell therapies, immunotherapies and other regenerative medicine applications. Our products are FDA- ...
  • Oxford BioMedica

    Stand: 802
    Oxford BioMedica is a leading gene-based biopharmaceutical company developing innovative medicines to improve the lives of patients with high unmet medical needs. We have established platform technolo ...
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman